Free Trial

Nexpoint Asset Management L.P. Has $727,000 Holdings in Bausch + Lomb Corporation $BLCO

Bausch + Lomb logo with Medical background

Key Points

  • Nexpoint Asset Management L.P. increased its holdings in Bausch + Lomb Corporation by 147.6%, owning 50,158 shares valued at approximately $727,000 by the end of the first quarter.
  • Multiple large investors have invested significantly in Bausch + Lomb, with Deutsche Bank AG acquiring a $50.75 million stake in the company during the same period.
  • Analysts have increased target prices for Bausch + Lomb, with estimates now ranging between $13.00 and $16.00, reflecting an overall consensus rating of "Hold".
  • Interested in Bausch + Lomb? Here are five stocks we like better.

Nexpoint Asset Management L.P. boosted its holdings in Bausch + Lomb Corporation (NYSE:BLCO - Free Report) by 147.6% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 50,158 shares of the company's stock after buying an additional 29,900 shares during the quarter. Nexpoint Asset Management L.P.'s holdings in Bausch + Lomb were worth $727,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Deutsche Bank AG acquired a new stake in Bausch + Lomb in the first quarter valued at about $50,750,000. Alberta Investment Management Corp raised its position in Bausch + Lomb by 8.6% in the first quarter. Alberta Investment Management Corp now owns 3,266,193 shares of the company's stock valued at $47,360,000 after purchasing an additional 258,000 shares during the last quarter. King Street Capital Management L.P. raised its position in Bausch + Lomb by 55.2% in the fourth quarter. King Street Capital Management L.P. now owns 1,136,321 shares of the company's stock valued at $20,522,000 after purchasing an additional 404,256 shares during the last quarter. Clark Estates Inc. NY raised its position in Bausch + Lomb by 3.7% in the first quarter. Clark Estates Inc. NY now owns 622,000 shares of the company's stock valued at $9,019,000 after purchasing an additional 22,000 shares during the last quarter. Finally, Tang Capital Management LLC raised its position in Bausch + Lomb by 28.6% in the fourth quarter. Tang Capital Management LLC now owns 450,000 shares of the company's stock valued at $8,127,000 after purchasing an additional 100,000 shares during the last quarter. 11.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BLCO has been the subject of several research reports. Morgan Stanley increased their target price on Bausch + Lomb from $12.00 to $13.00 and gave the company an "equal weight" rating in a research report on Friday, August 1st. Evercore ISI increased their target price on Bausch + Lomb from $15.50 to $16.00 and gave the company an "outperform" rating in a research report on Tuesday, July 8th. Zacks Research upgraded Bausch + Lomb to a "hold" rating in a research report on Tuesday, August 12th. HC Wainwright increased their target price on Bausch + Lomb from $15.00 to $16.00 and gave the company a "buy" rating in a research report on Thursday, July 31st. Finally, Wells Fargo & Company increased their target price on Bausch + Lomb from $12.00 to $15.00 and gave the company an "equal weight" rating in a research report on Thursday, July 31st. Three equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $15.56.

Check Out Our Latest Stock Analysis on BLCO

Bausch + Lomb Price Performance

Shares of BLCO opened at $14.61 on Friday. Bausch + Lomb Corporation has a 1 year low of $10.45 and a 1 year high of $21.69. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.55 and a quick ratio of 0.98. The company has a market capitalization of $5.17 billion, a price-to-earnings ratio of -18.72, a price-to-earnings-growth ratio of 1.49 and a beta of 0.63. The business has a 50-day moving average of $14.10 and a 200-day moving average of $13.47.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.06 by $0.01. Bausch + Lomb had a positive return on equity of 2.33% and a negative net margin of 5.58%.The company had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same period last year, the company earned $0.13 earnings per share. The firm's revenue was up 5.1% compared to the same quarter last year. Bausch + Lomb has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Bausch + Lomb Corporation will post 0.74 earnings per share for the current year.

Bausch + Lomb Company Profile

(Free Report)

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.

Further Reading

Want to see what other hedge funds are holding BLCO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch + Lomb Corporation (NYSE:BLCO - Free Report).

Institutional Ownership by Quarter for Bausch + Lomb (NYSE:BLCO)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Bausch + Lomb Right Now?

Before you consider Bausch + Lomb, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch + Lomb wasn't on the list.

While Bausch + Lomb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.